ImexpharmSTC:IMP -1.38%98 FCF Yield % is 4.22 as of Jun. 26, 2026, which is 2382% above its 10-year median of 0.17. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Imexpharm ranks better than 70.15% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Imexpharm FCF Yield % Related Terms
Imexpharm FCF Yield % Historical Data
* Premium members only.
The historical data trend for Imexpharm's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Imexpharm's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a FCF Yield % of 4.22 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imexpharm and its competitors. This is 2382% above median its historical median of 0.17. According to the industry distribution chart, Imexpharm ranks #300 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Imexpharm's FCF Yield % too high?
Imexpharm's current FCF Yield % of 4.22 is 2382% above median its 10-year median of 0.17. The Drug Manufacturers industry median FCF Yield % is 0.67. Imexpharm's value of 4.22 is 529.9% above this industry median. Based on the distribution chart, Imexpharm ranks #300 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #300 out of 1005 companies for FCF Yield %. This puts Imexpharm in the upper half of its industry. The industry median FCF Yield % is 0.67. Imexpharm's value of 4.22 is 529.9% above this benchmark. While the company's 10-year median is 0.17 vs. the industry median of 0.67, Imexpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current FCF Yield % of 4.22 is 529.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current FCF Yield % is 4.22, which is 2382% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,900.00 — trading 17% below its estimated fair value. The current FCF Yield % is 4.22, which is 2382% above median its 10-year median of 0.17 and 529.9% above the Drug Manufacturers industry median of 0.67. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current FCF Yield % is 4.22 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,900.00 is trading 17% below its estimated GF Value™ of ₫51,706.57.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
FCF Yield %: 4.22 (2382% above median its 10-year median of 0.17)
GF Value™: ₫51,706.57 vs. price of ₫42,900.00 (17% below fair value)
Industry Position: 529.9% above the Drug Manufacturers median (#300 of 1005)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
